OncLive Peer Exchange®

A panel of experts review several updates in myelodysplastic syndromes (MDS) that were presented at ASCO 2023 and other recent meetings and discuss how the data may change treatment approaches in clinical practice.

Expert panelists reflect on the current state of molecular testing and management in patients with metastatic colorectal cancer, reviewing recent clinical data and considering changes in real-world practice.

Key opinion leaders review recent clinical data in the field of multiple myeloma management and consider how the treatment paradigm has evolved.

Experts discuss several recent data updates in the treatment of myeloproliferative neoplasms (MPNs) and the impact on clinical practice.

Expert panelists review recent updates in the management of relapsed/refractory diffuse large B-cell lymphoma and consider how they have impacted the real-world treatment landscape and clinical practice.

Sponsored in part by Regeneron. Content independently created by OncLive.

A panel of experts discuss updates in immunotherapy for advanced non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment decision-making.

Key opinion leaders in the field of non–small cell lung cancer reflect on the evolving role of immunotherapy, alone or in combination, within various subsets of disease.

Centering discussion on clinical scenarios, expert oncologists work together to review updates in the treatment of differentiated thyroid cancer (DTC) that were presented at key conferences in 2022.

A panel of expert oncologists consider the role of HER2 expression in colorectal cancer and review novel targeted therapies in this setting.

Expert panelists reflect on the evolving treatment landscape of urothelial carcinomas and identify how it has impacted their real-world practices.

Expert panelists review updated data in the identification and management of resectable cutaneous squamous cell carcinoma and reflect on how real-world practice has evolved.

A panel of experts discuss data from recent clinical trials in renal cell carcinoma (RCC) presented at ASCO GU 2023 and other meetings, and its potential impact on clinical practice.

Expert panelists review new data on treatment and management of nmCRPC, mHSPC, and mCRPC and consider how these data may impact clinical practice.

Expert panelists review patient case studies and discuss key updates in the treatment landscape of advanced HCC from the 2023 ASCO Gastrointestinal Cancers Symposium and beyond.

A panel of experts review the evolving treatment landscape of biliary tract cancers contextualized with their real-world experiences.

An expert panel reviews the diagnosis and treatment of metastatic colorectal cancer with a focus on the setting of HER2-positive disease.

Expert perspectives on the evolving treatment landscape of HR+ breast cancer and how novel therapies have been incorporated in practice.

Expert perspectives on molecular testing and best practices for identifying patients who may be eligible for treatment with newly approved targeted therapies.

A panel made up of expert hematologists Ryan Cassaday, MD, Armin Ghobadi, MD, Elias Jabbour, MD, and Gary J. Schiller, MD discusses current standards-of-care in Acute Lymphoblastic Leukemia as well as key data presented at the American Society of Hematology’s 2022 Annual Meeting.

Expert oncologists review recent updates in the treatment of acute myeloid leukemia (AML) that were presented at key conferences in 2022.

Five experts in the field of MDS highlight recent data updates, including those presented at the 2022 American Society of Hematology (ASH) Annual Meeting.

A panel of experts summarizes the current HR+ breast cancer treatment landscape and discusses recent data updates in the field, including those presented at the 2022 San Antonio Breast Cancer Symposium (SABCS).

A distinguished panel of experts in hematologic malignancies have an engaging discussion on the current and potential future treatment approaches for MCL.

Expert hematologist-oncologists review key updates in the treatment of CLL presented at recent conferences and consider their impact on clinical practice.

Panel of oncologists define graft vs host disease (GvHD), review the current landscape and discuss the future of GvHD treatment.

Shared insight from a panel of key opinion leaders on the evolving treatment landscape of myeloproliferative neoplasms and improvements in care.

Sponsored in part by Amgen Oncology and Sanofi. Content independently created by OncLive.

Joseph Mikhael, MD, and panelists present a case of a 63-year-old woman with early relapse multiple myeloma and discuss the impact of updated trial data on treatment decision-making for patients.

A panel of key opinion leaders gather for a discussion on recent data updates in the treatment of multiple myeloma that were recently presented at ASH 2022, and how they impact clinical practice and treatment recommendations.

A panel of oncologists review recent data from the ZUMA-7 trial and provide a comprehensive review of thetreatment options for patients with R/R DLBCL.

A panel of esteemed nurse practitioners discusses how endometrial cancer is diagnosed, the process of treatment decision-making, and the management of adverse effects in patients undergoing treatment.